LANNETT CO INC
GenericsLANNETT CO INC is a generic drug manufacturer focused on Infectious Disease, Cardiovascular, Gastroenterology.
LANNETT CO INC's Key Drugs
LANNETT CO INC's core commercial portfolio centers on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, LOPINAVIR AND RITONAVIR, spanning Infectious Disease and Cardiovascular — its most strategically important drugs approved in the last 15 years.
LANNETT CO INC's Recent FDA Approvals
LANNETT CO INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
LANNETT CO INC's Therapeutic Areas
LANNETT CO INC's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LANNETT CO INC's Top Competitors
LANNETT CO INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Novo Nordisk, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LANNETT CO INC Pipeline Snapshot
LANNETT CO INC has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1955-10-12
- Latest
- 2026-06-18
- Applications
- 141